Exelixis, Inc. (EXEL) Insider Sells $658,857.43 in Stock

Exelixis, Inc. (NASDAQ:EXEL) insider Michael Morrissey sold 37,499 shares of the business’s stock in a transaction that occurred on Friday, November 2nd. The stock was sold at an average price of $17.57, for a total transaction of $658,857.43. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Michael Morrissey also recently made the following trade(s):

  • On Monday, October 1st, Michael Morrissey sold 12,501 shares of Exelixis stock. The stock was sold at an average price of $17.82, for a total transaction of $222,767.82.
  • On Monday, August 20th, Michael Morrissey sold 90,000 shares of Exelixis stock. The stock was sold at an average price of $17.82, for a total transaction of $1,603,800.00.
  • On Tuesday, August 7th, Michael Morrissey sold 100,000 shares of Exelixis stock. The stock was sold at an average price of $21.10, for a total transaction of $2,110,000.00.
  • On Thursday, August 9th, Michael Morrissey sold 234,267 shares of Exelixis stock. The stock was sold at an average price of $21.04, for a total transaction of $4,928,977.68.

Shares of Exelixis stock opened at $17.41 on Monday. Exelixis, Inc. has a 12-month low of $13.42 and a 12-month high of $32.20. The firm has a market capitalization of $5.19 billion, a PE ratio of 34.14 and a beta of 2.29.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Thursday, November 1st. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.22. Exelixis had a net margin of 49.53% and a return on equity of 63.91%. The business had revenue of $225.40 million during the quarter, compared to analysts’ expectations of $174.14 million. During the same quarter in the prior year, the business posted $0.26 EPS. The company’s revenue for the quarter was up 47.8% on a year-over-year basis. Sell-side analysts expect that Exelixis, Inc. will post 1.03 earnings per share for the current year.

Several institutional investors have recently modified their holdings of EXEL. BlackRock Inc. boosted its holdings in shares of Exelixis by 77.8% in the 2nd quarter. BlackRock Inc. now owns 28,997,375 shares of the biotechnology company’s stock valued at $624,024,000 after buying an additional 12,689,909 shares in the last quarter. First Trust Advisors LP boosted its holdings in shares of Exelixis by 78.6% in the 3rd quarter. First Trust Advisors LP now owns 4,643,726 shares of the biotechnology company’s stock valued at $82,287,000 after buying an additional 2,044,201 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Exelixis by 143.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 3,042,525 shares of the biotechnology company’s stock valued at $65,476,000 after buying an additional 1,790,454 shares in the last quarter. American Century Companies Inc. boosted its holdings in shares of Exelixis by 504.6% in the 2nd quarter. American Century Companies Inc. now owns 2,034,270 shares of the biotechnology company’s stock valued at $43,777,000 after buying an additional 1,697,822 shares in the last quarter. Finally, Macquarie Group Ltd. boosted its holdings in shares of Exelixis by 78.9% in the 2nd quarter. Macquarie Group Ltd. now owns 3,553,414 shares of the biotechnology company’s stock valued at $76,469,000 after buying an additional 1,566,890 shares in the last quarter. Institutional investors and hedge funds own 80.87% of the company’s stock.

EXEL has been the subject of several analyst reports. Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $25.00 price target for the company in a report on Tuesday, July 31st. Stifel Nicolaus lowered their price target on shares of Exelixis from $29.00 to $25.00 and set a “hold” rating for the company in a report on Wednesday, August 1st. BidaskClub cut shares of Exelixis from a “sell” rating to a “strong sell” rating in a report on Saturday, August 11th. Morgan Stanley initiated coverage on shares of Exelixis in a report on Monday, September 10th. They set an “underweight” rating and a $19.00 price target for the company. Finally, Goldman Sachs Group initiated coverage on shares of Exelixis in a report on Monday, September 17th. They set a “neutral” rating and a $22.00 price target for the company. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Exelixis currently has an average rating of “Buy” and a consensus price target of $29.78.

Exelixis Company Profile

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

See Also: Do stock splits help investors?

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply